The future of peptides in the US is about to become clearer. Here’s what you should know

Key Points:

• The FDA’s Pharmacy Compounding Advisory Committee will meet to consider whether to allow certain non-FDA-approved peptides to be dispensed by compounding pharmacies, potentially creating a regulated pathway for these popular but experimental treatments.
• The committee, now composed mainly of health professionals involved with peptides, will review seven peptides nominated for the FDA’s 503A Bulks List, which permits compounding pharmacies to prepare customized medications under specific conditions.
• FDA experts have expressed concerns over the lack of robust safety and efficacy data for these peptides, recommending against their addition to the compounding list, while supporters argue that regulated compounding could reduce risks associated with unregulated online purchases.
• Safety remains a major issue, as many peptides lack long-term clinical trial data, and experts warn that broader access could expose patients to unknown risks, though some practitioners report minimal adverse effects based on personal experience.
• If approved for compounding, these peptides could become more accessible through prescriptions and licensed pharmacies, potentially expanding their use but also raising questions about regulation, patient disclosure, and monitoring of adverse events.